Search results
Is Geron Stock a Buy Following Its First New Drug Approval?
Motley Fool via Yahoo Finance· 6 hours ago*Stock Advisor returns as of June 3, 2024 Cory Renauer has no position in any of the stocks...
FDA Warns Company Making Stem Cell Products for Pets
MedPage Today· 3 days agoFDA has sent a warning letter to a company that makes stem cell and platelet-rich plasma products -- for pets. The agency told Texas-based ...
Gene therapy and employee benefits: from science fiction to medical reality
BenefitsPRO· 5 days agoAs of late May 2024, 14 gene therapies are FDA-approved for a range of conditions including sickle ...
Stem Cells Fast Facts - ABC17NEWS
ABC17 NEWS· 3 days agoScientists believe that stem cell research can be used to treat medical conditions including Parkinson’s disease, spinal cord injury, stroke, burns, heart ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 4 days agoBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today ...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 5 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA
Seres sells VOWST assets to Nestlé Health Science By Investing.com
Investing.com· 2 days agoThe deal will see Seres receive an upfront payment along with additional financial considerations,...
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health...
Morningstar· 2 days agoSeres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science ...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Valley City Times Record· 5 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple myeloma who have ...
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis...
Benzinga· 4 days agoIn heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety
